MaxCyte Signs Platform License Agreement with Adicet Bio

MaxCyte’s Flow Electroporation^® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs

ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced it has signed a strategic platform license (SPL) with Adicet Bio, Inc., a biotechnology company focused on the development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.

Read more at globenewswire.com